ライフサイエンスコーパス: amitriptyline

1 nt therapy during hospitalization (nine with amitriptyline).

2 r fluoxetine to 0.48 [95% CI, 0.41-0.55] for amitriptyline).

3 T and Asm(-/-) mice and blockade of Asm with amitriptyline.

4 bitor chelerythrine diminished the effect of amitriptyline.

5 egabalin; 100-mg and 200-mg milnacipran; and amitriptyline.

6 esics or other pain-modulating drugs such as amitriptyline.

7 ld be imitated by incubation of T cells with amitriptyline.

8 of neuropathic pain, such as gabapentin and amitriptyline.

9 compared with use of headache education plus amitriptyline.

10 d the cannabinoid WIN 55,212-2, but not with amitriptyline.

11 as modulated by treatment with reserpine and amitriptyline.

12 amine cyproheptadine, and the antidepressant amitriptyline.

13 mpared with aged controls) after 6 months of amitriptyline.

14 (p < 0.05) decreased in the aged rats after amitriptyline.

15 lices treated with varying concentrations of amitriptyline (0-5 uM) and incubated with inhibitors tar

16 d, double-blind, placebo-controlled trial of amitriptyline (1 mg per kilogram of body weight per day)

17 95% confidence interval, [CI] 0.61-1.13) for amitriptyline, 1.16 (95% CI, 0.90-1.50) for fluoxetine,

18 afaxine, 1.54%), a tricyclic antidepressant (amitriptyline, 1.86%), and two atypical antidepressants

19 ere randomly assigned (1:1) to low-dose oral amitriptyline (10 mg once daily) or placebo for 6 months

20 sia were randomized to 4 weeks of placebo or amitriptyline (10 mg/d, weight <35 kg; 20 mg/d, weight >

21 used for the treatment of neuropathic pain, amitriptyline (10 mg/kg) and fluoxetine (5 mg/kg), to ra

22 ds maximum tolerated dose (75 mg per day for amitriptyline, 120 mg per day for duloxetine, and 600 mg

23 were randomly allocated to receive low-dose amitriptyline (232) or placebo (231).

24 46 (20%) participants discontinued low-dose amitriptyline (30 [13%] due to adverse events), and 59 (

25 fenpropidin, 23 ng/L), two antidepressants (amitriptyline, 304 ng/L, and paroxetine, 26 ng/L), and t

26 most commonly prescribed antidepressant was amitriptyline (45.2% of treated patients), administered

27 by 39 subjects given placebo (40%), 51 given amitriptyline (53%), and 37 given escitalopram (38%) (P

28 dized acupuncture regimen vs control points, amitriptyline (75 mg/d) vs placebo, or both for 14 weeks

29 and murine pRBCs were stored with or without amitriptyline, a functional inhibitor of acid sphingomye

30 Amitriptyline accumulated to a larger extent than predic

31 e tracking analysis, treatments of mice with amitriptyline (acid sphingomyelinase inhibitor), GW4869

32 serotonin-norepinephrine reuptake inhibitor Amitriptyline (AMI) for treatment of mental health probl

33 Drug Administration-approved antidepressant, amitriptyline (AMI) has shown efficacy in treating neuro

34 re (28 days) to the tricyclic antidepressant amitriptyline (AMI) on fish, including for concentration

35 In lesioned animals, chronic amitriptyline (AMI; 5 mg/kg) treatment resulted in a sig

36 Patients taking amitriptyline (AMT) have an increased risk of sudden car

37 Each group received 1 mg/kg/d of amitriptyline and a 20-week end point visit.

38 Additionally, for amitriptyline and amoxapine, the TRACT assay indicated d

39 Under voltage-clamp conditions, amitriptyline and bupivacaine remained as potent blocker

40 inergic and serotonergic antagonists such as amitriptyline and citalopram recapitulate this effect.

41 as previously reported for desipramine, both amitriptyline and fluoxetine increase the pain threshold

42 iked to the same concentration with the drug amitriptyline and imaged in the same experiment using is

43 d modified electrode was highly selective to Amitriptyline and it was shown a wide linear range from

44 This pattern of aODNs effect on amitriptyline and mianserin modulation of GABA-stimulate

45 The inhibitory effect of the antidepressants amitriptyline and mianserin on GABA-stimulated 36Cl(-) i

46 the GABA(A) receptor regulate the effect of amitriptyline and mianserin on the GABA(A) receptor chlo

47 failed response showed no difference between amitriptyline and placebo (P = .83).

48 There was no significant difference between amitriptyline and placebo after 4 weeks of treatment.

49 Both amitriptyline and placebo were associated with excellent

50 Longitudinal analyses showed that amitriptyline and topiramate did not explain intercept r

51 t adrenergic uptake inhibitors, specifically amitriptyline and trimipramine, could be potential thera

52 ns such as antidepressants (eg, mirtazapine, amitriptyline) and antihyperglycemics such as glyburide

53 , doxepin, amisulpride, chlorpheniramine, to amitriptyline, and atropine (the latter not for nocturna

54 ignificant results (flunarizine, riboflavin, amitriptyline, and cinnarizine), more studies were requi

55 ization energies of imipramine, desipramine, amitriptyline, and clomipramine are predicted using dens

56 ic antidepressants: imipramine, desipramine, amitriptyline, and clomipramine.

57 ith pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabal

58 aimed wastewater: carbamazepine, fluoxetine, amitriptyline, and lamotrigine.

59 date, sertraline hydrochloride, ondansetron, amitriptyline, and melatonin were the only medications i

60 Topiramate, valproate, propranolol, amitriptyline, and methysergide have been widely prescri

61 , including testosterone, 17 beta-estradiol, amitriptyline, and most notably aflatoxin (AF) B1.

62 d feeling better and 5% feeling worse in the amitriptyline arm compared with 57.5% feeling better and

63 in the same experiment using isotope labeled amitriptyline as internal standard.

64 nth follow-up; again, half were treated with amitriptyline at doses of 10-30 mg/day.

65 Amitriptyline at low-dose and titrated for irritable bow

66 sed, double-blind, placebo-controlled trial (Amitriptyline at Low-Dose and Titrated for Irritable Bow

67 Chronic antidepressant treatment with amitriptyline attenuated the maladaptive neurogenic, epi

68 ropion (beta [SE]: -0.063 [0.027]; P = .02), amitriptyline (beta [SE]: -0.081 [0.025]; P = .001), and

69 68.10%) on 20 antidepressants (agomelatine, amitriptyline, bupropion, citalopram, desvenlafaxine, du

70 mmasome activation in glomeruli during hHcy, amitriptyline (but not GW4869 and rapamycin) was shown t

71 Amitriptyline, but not escitalopram, appears to benefit

72 lly efficacious as gabapentin (Neurontin) or amitriptyline, but respectively >350- and >75-fold more

73 t on heat hypersensitivity was observed with amitriptyline, carbamazepine, diazepam and gabapentin.

74 n tactile hypersensitivity was observed with amitriptyline, carbamazepine, rofecoxib, and diazepam.

75 The determination of amitriptyline, citalopram, clomipramine, chlorpromazine,

76 We included trials of amitriptyline, citalopram, clomipramine, desipramine, du

77 In terms of the 6-month relapse rate, amitriptyline, citalopram, desvenlafaxine, duloxetine, f

78 -0.08 (95% CI, -0.21 to 0.06; P=.26) and for amitriptyline compared with placebo was 0.00 (95% CI, -0

79 points option), and 136 patients were in the amitriptyline comparison (125 in the factorial option an

80 For both the acupuncture and amitriptyline comparisons, changes in pain score were no

81 of plants to carbamazepine and fluoxetine or amitriptyline decreased accumulation of the toxic carbam

82 e data suggest that long-term treatment with amitriptyline decreases the prevalence of cognitive impa

83 from rats chronically (14 days) administered amitriptyline demonstrates that TNF inhibition of NE rel

84 hma, there is emerging evidence that inhaled amitriptyline directly reduces acute bronchoconstriction

85 CD), a common substance to destroy caveolae, amitriptyline dramatically reduced the number of caveola

86 oniazid, nefazodone, phenelzine, imipramine, amitriptyline, duloxetine, bupropion, trazodone, tianept

87 Most guidelines recommend amitriptyline, duloxetine, pregabalin, or gabapentin as

88 This amitriptyline effect is opposite to the inhibition of GA

89 es that the mixed action antidepressant drug amitriptyline enhances norepinephrine (NE) release by tr

90 either mean rate of headache days per week (amitriptyline: estimate [SE], 0.07 [0.05]; P = .16; topi

91 or headache disability PedMIDAS total score (amitriptyline: estimate [SE], 0.25 [0.38]; P = .52; topi

92 pressant treatment is similar among users of amitriptyline, fluoxetine, and paroxetine compared with

93 Administration of the antidepressant drug amitriptyline for 1 day or 14 days to rats significantly

94 group vs 6.8 for the headache education plus amitriptyline group (difference, 4.7 [95% CI, 1.7-7.7] d

95 than 20 points were assigned to the CBT plus amitriptyline group (n = 64) or the headache education p

96 roup (n = 64) or the headache education plus amitriptyline group (n = 71).

97 vs. 14%) and dry mouth (25% vs. 12%) in the amitriptyline group and paresthesia (31% vs. 8%) and wei

98 e five serious adverse reactions (two in the amitriptyline group and three in the placebo group), and

99 Three patients in the amitriptyline group had serious adverse events of altere

100 adache were reduced by 11.5 for the CBT plus amitriptyline group vs 6.8 for the headache education pl

101 0.11 to 0.12; P=.88) and for patients in the amitriptyline group vs those in the placebo group was -0

102 in the primary efficacy analysis (132 in the amitriptyline group, 130 in the topiramate group, and 66

103 which occurred in 52% of the patients in the amitriptyline group, 55% of those in the topiramate grou

104 lease from podocytes, which was prevented by amitriptyline, GW4869, and rapamycin.

105 compounded topical gel containing baclofen, amitriptyline HCL, and ketamine, these agents may be off

106 index antidepressant prescription including amitriptyline hydrochloride, bupropion hydrochloride, ci

107 observed for clozapine, quetiapine fumarate, amitriptyline hydrochloride, mirtazapine, nortriptyline

108 ssigned to receive tricyclic antidepressant (amitriptyline hydrochloride, up to 100 mg/d, or nortript

109 ith the pharmaceutical drugs; Cetirizine and Amitriptyline hydrochloride.

110 Results showed that Amitriptyline, Imipramine, Paroxetine, and Sertraline ha

111 difenoxin) and the tricyclic antidepressant amitriptyline improve continence in patients with diarrh

112 logical role of the tricyclic antidepressant amitriptyline in bronchial asthma, there is emerging evi

113 f this study was to evaluate the efficacy of amitriptyline in children with pain-predominant function

114 ve immunoassay for the detection of the drug amitriptyline in human serum.

115 significant difference in favour of low-dose amitriptyline in IBS-SSS score between groups at 6 month

116 he model was fitted to the concentrations of amitriptyline in plasma and the heart.

117 om protonated nordoxepin, nortriptyline, and amitriptyline increase almost 1 order of magnitude acros

118 Furthermore, chronic administration of amitriptyline increases stimulation-evoked NE release an

119 Of relevance, amitriptyline-induced ASMase inhibition in human hepatoc

120 However, the mechanism by which amitriptyline influences bronchial tone remains poorly u

121 Treatment of pRBCs with amitriptyline inhibited acid sphingomyelinase activity,

122 In conclusion, amitriptyline inhibits bronchoconstriction independently

123 ine: IRR=1.22, 95% CI=1.12-1.32), switching (amitriptyline: IRR=1.45, 95% CI=1.15-1.81; venlafaxine:

124 Amitriptyline is a common antidepressant; however, it ha

125 Amitriptyline is an established medication used off-labe

126 t for the analysis of verapamil, citalopram, amitriptyline, lidocaine, and sunitinib in dried blood s

127 Neither amitriptyline nor escitalopram appeared to affect GE or

128 Amitriptyline, nortriptyline, desipramine, clomipramine,

129 tion for the following nine antidepressants: amitriptyline, nortriptyline, desipramine, clomipramine,

130 g to adverse drug reactions) associated with amitriptyline (off-label), pregabalin, duloxetine, and m

131 ions, a decreased relapse risk was found for amitriptyline-olanzapine (aHR=0.45, 95% CI: 0.28-0.71),

132 zation), influenced the inhibitory effect of amitriptyline on bronchoconstriction.

133 rison (125 in the factorial option and 11 in amitriptyline option vs placebo option).

134 Co-application of amitriptyline or bupivacaine, which targeted the LA rece

135 ated after transfusion of pRBCs treated with amitriptyline or from acid sphingomyelinase-deficient mi

136 l, 2.1 to 2.8) for doses of 50 mg or more of amitriptyline or its equivalent, and for the serotonin-r

137 actions in podocytes, which was prevented by amitriptyline or rapamycin but not GW4869.

138 Patients who received amitriptyline or topiramate had higher rates of several

139 y (higher dropout rate) than placebo, except amitriptyline (OR, 0.78; 95% CrI, 0.31 to 1.66).

140 omly assigned to groups given placebo, 50 mg amitriptyline, or 10 mg escitalopram for 10 weeks.

141 double-blind 2 x 2 factorial design of SAR, amitriptyline, or the combination compared with placebo,

142 15% and good in 35% of children treated with amitriptyline (P = .85).

143 egabalin (A-P), pregabalin supplemented with amitriptyline (P-A), and duloxetine supplemented with pr

144 were investigated for three different drugs: amitriptyline, promethazine, and methadone.

145 treatment of wt mice with the Asm inhibitor amitriptyline recapitulated the phenotype of Asm-deficie

146 Amitriptyline reduced anxiety scores (P < .0001).

147 Amitriptyline reduces acetylcholine- and serotonin-induc

148 Treatment with amitriptyline reduces MP generation in vitro and in vivo

149 y after 2002, while rates for fluoxetine and amitriptyline remained stable.

150 s with chronic migraine, the use of CBT plus amitriptyline resulted in greater reductions in days wit

151 piramate (RoM, 0.70; 95% CI, 0.55-0.89), and amitriptyline (RoM, 0.73; 95% CI, 0.54-0.97) were also a

152 eniramine (RR = 2.20, 95% C.I. = 1.67-2.89), amitriptyline (RR = 2.09, 95% C.I. = 1.34-3.26), atropin

153 Adverse events were higher with amitriptyline (RR, 3.81; 95% CI, 1.41-10.32), topiramate

154 um sensitizing and induction failed to alter amitriptyline's effect on bronchoconstriction.

155 ne, as cholesterol repletion did not reverse amitriptyline's effect.

156 and successfully developed and validated as Amitriptyline sensor using cyclic voltammetry (CV), chro

157 tine (SMD, -1.33 [CrI, -1.82 to -0.86]), and amitriptyline (SMD, -0.72 [CrI, -1.35 to -0.08]) were mo

158 amate (SMD, 0.20; 95% CI, -0.36 to 0.76), or amitriptyline (SMD, 0.29; 95% CI, -0.17 to 0.76).

159 d sequences of the three treatment pathways: amitriptyline supplemented with pregabalin (A-P), pregab

160 Comparison of amitriptyline supplemented with pregabalin, pregabalin s

161 ed 36Cl- response to GABA in the presence of amitriptyline that is increased by flumazenil, unlike au

162 General practitioners should offer low-dose amitriptyline to patients with IBS whose symptoms do not

163 ty in childhood and adolescent migraine with amitriptyline, topiramate, or placebo over a period of 2

164 HAMP trial, which randomized participants to amitriptyline, topiramate, or placebo.

165 ) but is similar to that seen in tissue from amitriptyline-treated rats or dominant rats.

166 Amitriptyline treatment from midlife preserved water maz

167 ged male Lister hooded rats (16 months) with amitriptyline until they were 24 months of age, and thei

168 Recommended preventive treatments include amitriptyline, venlafaxine and mirtazapine, as well as s

169 trol points, or (3) a double-blind design of amitriptyline vs placebo.

170 roup, and 61% of those in the placebo group (amitriptyline vs. placebo, P=0.26; topiramate vs. placeb

171 ebo, P=0.26; topiramate vs. placebo, P=0.48; amitriptyline vs. topiramate, P=0.49).

172 cacy for treating pain and depression, while amitriptyline was associated with higher efficacy for im

173 Compared with placebo, amitriptyline was associated with reduced sleep disturba

174 The total cardiac clearance of amitriptyline was calculated as 0.316 L/h.

175 In this study, neither acupuncture nor amitriptyline was more effective than placebo in relievi

176 The combination of fluoxetine and amitriptyline was reported to be more beneficial than ei

177 Titrated low-dose amitriptyline was superior to placebo as a second-line t

178 Subjects with ulcer-like FD given amitriptyline were >3-fold more likely to report adequat

179 f host acid sphingomyelinase, imipramine and amitriptyline, which induce degradation of the cellular